期刊文献+

基于贝叶斯最优区间设计确定药物最大耐受剂量 被引量:1

Determination of maximum tolerated dose of drugs based on Bayesian optimal interval design
原文传递
导出
摘要 选择合适的方法探索药物的最大耐受剂量(MTD)一直是Ⅰ期耐受性试验设计的要点。贝叶斯最优区间(BOIN)设计是一种新颖的确定MTD的模型辅助设计,兼顾规则设计的简单性及模型设计的良好特性,具有可操作性强、安全性高、识别MTD准确性高、灵活高效等优点。本研究模拟临床试验,采用BOIN设计进行操作说明。 To select the appropriate method to explore the maximum tolerated dose(MTD)of drugs has been the main point of the design of phaseⅠtolerance trials.Bayesian optimal interval(BOIN)design is a novel model-assisted design for determining MTD,which combines the simplicity of rule-design with the good characteristics of model-design,with the advantages of strong operability,high security,high accuracy of MTD identification,flexibility and efficiency.This study simulates clinical trial using BOIN design to explain the operation procedures.
作者 沈庆 孙瑞华 郝肖迪 虞康达 吴婉玲 肖畅 王蜜源 SHEN Qing;SUN Rui-hua;HAO Xiao-di;YU Kang-da;WU Wan-ling;XIAO Chang;WANG Mi-yuan(School of Management,Beijing University of Chinese Medicine,BEIJING 100029,China;Clinical Research Data and Project Management Platform,China-Japan Friendship Hospital,BEIJING 100029,China)
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2019年第9期533-536,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 贝叶斯最优区间 最大耐受剂量 临床试验 Ⅰ期 贝叶斯定理 Bayesian optimal interval maximum tolerated dose clinical trial,phaseⅠ Bayes theorem
  • 相关文献

参考文献3

二级参考文献18

  • 1Ashby D. Bayesian Statistics in Medicine: A 25 Year Review[J]. Statistics in Medicine, 2006(25). 被引量:1
  • 2Berry D A. Bayesian Clinical Trials[J]. Nature Reviews Drug Discovery, 2006(5). 被引量:1
  • 3Biswas S, Liu D D, Lee J J,Berry D A. Bayesian Clinical Trials at the University of Texas M. D. Anderson Cancer Center [J]. Clinical Trials,2009(6). 被引量:1
  • 4Berry S M, Carlin B P, Lee J J, Muller P. Bayesian Adaptive Methods Forelinieal Trials[M]. Chapman&Hall: Boca Raton, 2010. 被引量:1
  • 5Chevret S. Bayesian Adaptive Clinical Trials: A Dream for Statisticians only[J]. Statistics in Medicine, 2011 (5). 被引量:1
  • 6FDA, CDRH. Draft FDA Guidance on the Use of Bayesian Statistics for Medical Devices Trials[Z]. 2006. 被引量:1
  • 7中国国家药品与食品监管局.药物I期临床试验管理指导原则(征求意见稿)[S].2011. 被引量:1
  • 8Ji Y, Li Y S, Bekele B N. Dose-Finding in Phase Lclinical Trials Based on Toxicity Probability Intervals[J]. Clinical Trials, 2007(4). 被引量:1
  • 9O'Quigle J, Pepe M, Fisher L. Continual Reassessment Method: A Practical Design for Phase I Clinical Trials in Cancer [J]. Biometrics, 1990(46). 被引量:1
  • 10Ji Y, Li Y, Bekelen B N. Dose Finding in Phase I Clinical Trials Based on Toxicity Probability Intervals[J]. Clinical Trials, 2007(4). 被引量:1

共引文献6

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部